外科理论与实践

外科理论与实践 >

2020 , Vol. 25 >Issue 03: 269 - 272

DOI: https://doi.org/10.16139/j.1007-9610.2020.03.019

综述

长链非编码RNA与HER2阳性乳腺癌曲妥珠单抗耐药研究进展

展开
  • 上海交通大学医学院附属瑞金医院外科 乳腺疾病诊治中心,上海 200025

收稿日期: 2019-01-21

  网络出版日期: 2020-05-25

基金资助

上海教育委员会高峰高原计划——研究型医师(20172007)

收起

Advancement in study on long non⁃coding RNA and trastuzumab resistance of HER2 positive breast cancer

Expand

Received date: 2019-01-21

  Online published: 2020-05-25

Fold

本文引用格式

曹玮, 陈小松, 沈坤炜 . 长链非编码RNA与HER2阳性乳腺癌曲妥珠单抗耐药研究进展[J]. 外科理论与实践, 2020 , 25(03) : 269 -272 . DOI: 10.16139/j.1007-9610.2020.03.019

参考文献

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1):7-30.
[2] Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer[J]. Science, 1989, 244(4905):707-712.
[3] Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene[J]. Science, 1987, 235(4785):177.
[4] Martine JPG, Marion P, Brian LJ, et al. Trastuzumab after adjuvant chemotherapy in her2-positive breast cancer[J]. N Engl J Med, 2005, 353(16):1659-1672.
[5] 中国女医师协会临床肿瘤学专业委员会, 中国抗癌协会乳腺癌专业委员. 中国进展期乳腺癌共识(CABC 2015)[J]. 癌症进展, 2015, 13(3):223-245.
[6] Ning S, Zhang J, Wang P, et al. Lnc2Cancer: a manually curated database of experimentally supported lncRNAs associated with various human cancers[J]. Nucleic Acids Res, 2016, 44(D1):D980-D985.
[7] Chen G, Wang Z, Wang D, et al. LncRNADisease: a database for long-non-coding RNA-associated diseases[J]. Nucleic Acids Res, 2013, 41(Database issue):D983-D986.
[8] Xue X, Yang YA, Zhang A, et al. LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer[J]. Oncogene, 2016, 35(21):2746-2755.
[9] Lu R, Zhang J, Zhang W, et al. Circulating HOTAIR expression predicts the clinical response to neoadjuvant chemotherapy in patients with breast cancer[J]. Cancer Biomark, 2018, 22(2):249-256.
[10] Wu C, Luo J. Long non-coding RNA (lncRNA) urothelial carcinoma-associated 1 (UCA1) enhances tamoxifen resistance in breast cancer cells via inhibiting mTOR signa-ling pathway[J]. Med Sci Monit, 2016,22:3860-3867.
[11] Zhu HY, Bai WD, Ye XM, et al. Long non-coding RNA UCA1 desensitizes breast cancer cells to trastuzumab by impeding miR-18a repression of Yes-associated protein 1[J]. Biochem Biophys Res Commun, 2018, 496(4):1308-1313.
[12] Campos-Parra AD, Lopez-Urrutia E, Orozco Moreno LT, et al. Long non-coding RNAs as new master regulators of resistance to systemic treatments in breast cancer[J]. Int J Mol Sci, 2018, 19(9):2711.
[13] Dong H, Wang W, Mo S, et al. Long non-coding RNA SNHG14 induces trastuzumab resistance of breast cancer via regulating PABPC1 expression through H3K27 acetylation[J]. J Cell Mol Med, 2018, 22(10):4935-4947.
[14] Dong H, Wang W, Mo S, et al. SP1-induced lncRNA AGAP2-AS1 expression promotes chemoresistance of breast cancer by epigenetic regulation of MyD88[J]. J Exp Clin Cancer Res, 2018, 37(1):202.
[15] Li W, Zhai L, Wang H, et al. Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer[J]. Oncotarget, 2016, 7(19):27778-27786.
[16] Li GY, Wang W, Sun JY, et al. Long non-coding RNAs AC026904.1 and UCA1: a “one-two punch” for TGF-β-induced SNAI2 activation and epithelial-mesenchymal transition in breast cancer[J]. Theranostics, 2018, 8(10):2846-2861.
[17] 李小燕, 贺靖, 邹强. 乳腺癌外泌体及相关miRNA的研究进展[J]. 外科理论与实践, 2018, 23(6):564-568.
[18] 金泽宇, 陈小松. 循环肿瘤DNA在乳腺癌诊治中应用的研究[J]. 外科理论与实践, 2018, 23(5):473-476.
[19] Qu L, Ding J, Chen C, et al. Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA[J]. Cancer Cell, 2016, 29(5):653-668.
[20] Dong H, Wang W, Chen R, et al. Exosome-mediated transfer of lncRNA-SNHG14 promotes trastuzumab chemoresistance in breast cancer[J]. Int J Oncol, 2018, 53(3):1013-1026.
[21] Su X, Malouf GG, Chen Y, et al. Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes[J]. Oncotarget, 2014, 5(20):9864-9876.
[22] Lee J, Park HY, Kim WW, et al. Biological function of long noncoding RNA snaR in HER2-positive breast cancer cells[J]. Tumour Biol, 2017, 39(6):1010428317707374. doi: 10.1177/1010428317707374.
[23] Merry CR, Mcmahon S, Thompson CL, et al. Integrative transcriptome-wide analyses reveal critical HER2-regulated mRNAs and lincRNAs in HER2+ breast cancer[J]. Breast Cancer Res Treat, 2015, 150(2):321-334.
[24] Merry CR, Mcmahon S, Forrest ME, et al. Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer[J]. Oncotarget, 2016, 7(33):53230-53244.
[25] Yang F, Lyu S, Dong S, et al. Expression profile analysis of long noncoding RNA in HER-2-enriched subtype breast cancer by next-generation sequencing and bioinformatics[J]. Onco Targets Ther, 2016, 9:761-772.
Options
文章导航

/

〈 〉